Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
LncRNA PVT1 regulates triple-negative breast cancer through KLF5/beta-catenin signaling.
Oncogene ( IF 6.9 ) Pub Date : 2018-Aug-01 , DOI: 10.1038/s41388-018-0310-4 Jianming Tang , Yanxin Li , Youzhou Sang , Bo Yu , Deguan Lv , Weiwei Zhang , Haizhong Feng
Oncogene ( IF 6.9 ) Pub Date : 2018-Aug-01 , DOI: 10.1038/s41388-018-0310-4 Jianming Tang , Yanxin Li , Youzhou Sang , Bo Yu , Deguan Lv , Weiwei Zhang , Haizhong Feng
Recent molecularly targeted approach gains advance in breast cancer treatment. However, the estimated 5-year survival rate has not met the desired expectation for improvement, especially for patients with triple-negative breast cancer (TNBC). Here we report that the lncRNA PVT1 promotes KLF5/beta-catenin signaling to drive TNBC tumorigenesis. PVT1 is upregulated in clinical TNBC tumors. Using genetic approaches targeting PVT1 in TNBC cells, we found that PVT1 depletion inhibited cell proliferation, colony formation, and orthotopic xenograft tumor growth. Mechanistically, PVT1 binds with KLF5 and increases its stability via BAP1, which upregulates beta-catenin signaling, resulting in enhanced TNBC tumorigenesis. PVT1, KLF5, and beta-catenin were also revealed to be co-expressed in clinical TNBC samples. Our findings uncover a new singaling pathway to mediate TNBC, and provide PVT1 as a new target for improving treatment of TNBC.
更新日期：2018-05-15
京公网安备 11010802027423号